文献速递临床试验与 GCP

澳大利亚恶性胸腔积液(AMPLE)-3试验:比较留置胸腔导管(±滑石粉胸膜固定术)与电视辅助胸腔镜手术治疗恶性胸腔积液的多中心随机研究方案

Australasian Malignant PLeural Effusion (AMPLE)-3 trial: study protocol for a multi-centre randomised study comparing indwelling pleural catheter (±talc pleurodesis) versus video-assisted thoracoscopic surgery for management of malignant pleural effusion.
PubMed 文献 · Trials · 2022-06-27

AMPLE-3是一项多中心、开放标签随机试验,纳入症状性恶性胸腔积液、预期生存≥6个月且体能状态良好的患者,按1:1随机分配至留置胸腔导管(IPC)或电视辅助胸腔镜手术(VATS)胸膜固定术。主要结局为12个月内或死亡前(以先发生者为准)是否需要同侧进一步胸膜干预。计划招募158名参与者,随访12个月。

要点

  • AMPLE-3是首个在适合手术的患者中比较IPC(±滑石粉胸膜固定术)与VATS胸膜固定术的随机试验。
  • 主要结局为12个月内或死亡前(以先发生者为准)需要进一步同侧胸膜干预。
  • 计划招募158名参与者,随访12个月,随机化按癌症类型、既往胸膜固定术及 trapped lung 进行最小化。

核心结论

  • AMPLE-3试验将提供数据以帮助明确IPC和VATS这两种常用手术的优缺点,并为未来临床诊疗流程提供信息。

研究设计与样本

  • 多中心、开放标签随机试验,纳入症状性恶性胸腔积液、预期生存≥6个月且体能状态良好的患者,按1:1随机分配至IPC或VATS胸膜固定术。
  • 随机化按癌症类型(间皮瘤 vs 非间皮瘤)、既往胸膜固定术(有 vs 无)及已知的 trapped lung(有 vs 无)进行最小化。
  • 计划招募158名参与者,随访12个月。

主要发现

  • 主要结局为12个月内或死亡前(以先发生者为准)需要进一步同侧胸膜干预。
  • 次要结局包括住院天数、生活质量(QoL)指标、体力活动水平、安全性特征、卫生经济学、不良事件和生存。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Malignant pleural effusions (MPEs) are common. MPE causes significant breathlessness and impairs quality of life. Indwelling pleural catheters (IPC) allow ambulatory drainage and reduce hospital days and re-intervention rates when compared to standard talc slurry pleurodesis. Daily drainage accelerates pleurodesis, and talc instillation via the IPC has been proven feasible and safe. Surgical pleurodesis via video-assisted thoracoscopic surgery (VATS) is considered a one-off intervention for MPE and is often recommended to patients who are fit for surgery. The AMPLE-3 trial is the first randomised trial to compare IPC (±talc pleurodesis) and VATS pleurodesis in those who are fit for surgery. METHODS AND ANALYSIS: A multi-centre, open-labelled randomised trial of patients with symptomatic MPE, expected survival of ≥ 6 months and good performance status randomised 1:1 to either IPC or VATS pleurodesis. Participant randomisation will be minimised for (i) cancer type (mesothelioma vs non-mesothelioma); (ii) previous pleurodesis (vs not); and (iii) trapped lung, if known (vs not). Primary outcome is the need for further ipsilateral pleural interventions over 12 months or until death, if sooner. Secondary outcomes include days in hospital, quality of life (QoL) measures, physical activity levels, safety profile, health economics, adverse events, and survival. The trial will recruit 158 participants who will be followed up for 12 months. ETHICS AND DISSEMINATION: Sir Charles Gairdner and Osborne Park Health Care Group (HREC) has approved the study (reference: RGS356). Results will be published in peer-reviewed journals and presented at scientific meetings. DISCUSSION: Both IPC and VATS are commonly used procedures for MPE. The AMPLE-3 trial will provide data to help define the merits and shortcomings of these procedures and inform future clinical care algorithms. TRIAL REGISTRATION: Australia New Zealand Clinical Trial Registry ACTRN12618001013257 . Registered on 18 June 2018. PROTOCOL VERSION: Version 3.00/4.02.19.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Fitzgerald DB, Sidhu C, Budgeon C, et al. Australasian Malignant PLeural Effusion (AMPLE)-3 trial: study protocol for a multi-centre randomised study comparing indwelling pleural catheter (±talc pleurodesis) versus video-assisted thoracoscopic surgery for management of malignant pleural effusion. Trials. 2022. PMID: 35761341. doi:10.1186/s13063-022-06405-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。